402 related articles for article (PubMed ID: 25388353)
1. Snail is an independent prognostic indicator for predicting recurrence and progression in non-muscle-invasive bladder cancer.
Gou Y; Ding W; Xu K; Wang H; Chen Z; Tan J; Xia G; Ding Q
Int Urol Nephrol; 2015 Feb; 47(2):289-93. PubMed ID: 25388353
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
3. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
[TBL] [Abstract][Full Text] [Related]
4. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
5. Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study.
Santi R; Cai T; Nobili S; Galli IC; Amorosi A; Comperat E; Nesi G
Virchows Arch; 2018 Apr; 472(4):605-613. PubMed ID: 29525824
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
7. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843
[TBL] [Abstract][Full Text] [Related]
8. Tumor Suppressor in Lung Cancer-1 Is a Prognostic Predictor for the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer.
Chen Y; Yang Y; Liu L; Wang S; Song H; Liu X
Urol Int; 2016; 96(2):142-7. PubMed ID: 26894268
[TBL] [Abstract][Full Text] [Related]
9. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
11. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
12. High expression of spindle and kinetochore- associated protein 1 predicts early recurrence and progression of non-muscle invasive bladder cancer.
Jiang S; Tian F; Wang Q; Cheng W; Wang L; Wang Y; Sun W
Cancer Biomark; 2018; 22(3):543-549. PubMed ID: 29865039
[TBL] [Abstract][Full Text] [Related]
13. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
15. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups.
Ding W; Tong S; Gou Y; Sun C; Wang H; Chen Z; Tan J; Xu K; Xia G; Ding Q
World J Urol; 2015 Dec; 33(12):1951-7. PubMed ID: 25894367
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.
Abufaraj M; Shariat SF; Haitel A; Moschini M; Foerster B; Chłosta P; Gust K; Babjuk M; Briganti A; Karakiewicz PI; Albrecht W
Urol Oncol; 2017 May; 35(5):264-271. PubMed ID: 28214283
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer.
Zhao J; Dong D; Sun L; Zhang G; Sun L
Int Braz J Urol; 2014; 40(2):179-89. PubMed ID: 24856504
[TBL] [Abstract][Full Text] [Related]
20. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]